Our Take
The real story is not which class wins, but that oncology has moved past false binaries—both work, and patient selection, not drug category, now determines outcome.
Why it matters
Clinicians choosing between bispecifics and ADCs need data on head-to-head efficacy and safety trade-offs, not marketing positioning. ASCO is where that data surfaces first, shaping treatment protocols within months.
Do this week
Oncology teams: request independent efficacy comparisons (not vendor slides) before adopting either drug class into standard protocols this quarter.
Bispecifics and ADCs squared off on efficacy
At the American Society of Clinical Oncology annual meeting in 2026, two dominant antibody-based drug classes collided over clinical trial results. Bispecific antibodies (molecules that bind two targets simultaneously) and antibody-drug conjugates (antibodies chemically linked to cytotoxic payloads) presented competing efficacy data, each claiming advantages in specific cancer settings.
The conflict emerged because both classes target similar patient populations—particularly in HER2-positive and hormone-receptor positive cancers—using different mechanisms. Bispecifics rely on dual engagement and immune activation. ADCs depend on targeted payload delivery. Trial results from both classes showed clinical benefit, but in different cohorts and with different safety profiles.
RAS mutations are no longer a treatment wall
Separately, researchers reported progress on a once-intractable problem: RAS-mutant cancers. RAS mutations occur in roughly 30% of human cancers and have historically resisted targeted therapy because the RAS protein is difficult to drug. The reported breakthrough suggests new inhibitors or combination approaches are now viable in this patient population.
This matters because RAS-mutant tumors have been a graveyard for precision oncology. Clinicians have had chemotherapy as the primary option. If new agents can reliably suppress RAS-driven growth, entire treatment algorithms shift, and a large patient cohort gains access to more targeted, potentially less toxic options.
The bispecific-versus-ADC debate and RAS progress are separate findings, but they reflect a broader pattern: oncology is moving from class-based thinking to mechanism-specific, patient-specific selection. Neither bispecifics nor ADCs will dominate universally. Efficacy depends on tumor biology, prior treatment, and individual immune status, not on the drug scaffold alone.
Stop waiting for a category winner
Oncology teams evaluating these agents should stop asking "which class is better" and start asking "which mechanism fits this patient's tumor biology and prior exposure." Request head-to-head trial data or matched-cohort analyses that control for patient factors, not just side-by-side press releases.
For RAS-mutant cases, request trial data on response rates, progression-free survival, and safety before committing institutional adoption. If new RAS inhibitors are viable, your protocols will need rapid updates. Build that change-management process now, before the data becomes standard of care and other centers move faster.